Muskeldystrophie Typ Duchenne

A. von Moers

doi:10.1055/s-0038-1628428

Nervenheilkunde, Table of Contents

Nervenheilkunde 2011; 30(10): 805-812
DOI: 10.1055/s-0038-1628428

Deutsche Gesellschaft für Muskelkranke

Schattauer GmbH

Muskeldystrophie Typ Duchenne

Duchenne muscular dystrophy

A. von Moers

¹Klinik für Kinderund Jugendmedizin, DRK Kliniken Berlin

› Author Affiliations

Abstract

Zusammenfassung

Die Muskeldystrophie Duchenne ist eine X-gebundene rezessive Erkrankung, die bei 1:3 500 Knaben auftritt. Sie wird durch Mutationen im DMD-Gen verursacht. Die Mutationen resultieren in einem Verlust von Dystrophin, dies führt zur progredienten Muskeldegeneration. Der Krankheitsverlauf ist durch eine progrediente, proximal betonte Muskelschwäche gekennzeichnet, die ohne Behandlung zu einem Gehverlust um das 10. Lebensjahr und zum frühzeitigen Tod um das 20. Lebensjahr durch Ateminsuffizienz oder Herzversagen führt. Durch symptomatische Therapien kann der Krankheitsverlauf positiv beeinflusst werden, besonders durch die Etablierung der nicht invasiven Beatmung konnte die Lebenserwartung erheblich verlängert werden. In den letzten Jahren wurden verschiedene Ansätze einer kausalen Therapie untersucht. Am weitesten gediehen ist das “exon skipping”, dessen Wirksamkeit in internationalen, multizentrischen Phase-III Studien untersucht wird.

Summary

Duchenne muscular dystrophy is an X-linked recessive disease that affects about 1:3 500 male birth. It is caused by mutations of the DMD gene. Mutations lead to a loss of dystrophin which results in progressive muscle degeneration. The phenotype is characterised by a progressive proximal pronounced muscle weakness. Without intervention a wheelchair is required in the beginning of the teens and death occurs at about 20^th year of life because of respiratoy or cardiac failure. Comprehensive multidisciplinary management can improve the course of disease, in particular the implementation of non-invasive ventilation remarkably prolonged life expectancy. Several gene therapeutic approaches are under examination. At present efficacy of exon skipping is investigated in international multicenter clinical trials.

Schlüsselwörter

Duchenne - Phänotyp - interdisziplinäre Betreuung - exon skipping

Keywords

Duchenne - phenotype - multidisciplinary management - exon skipping

Full Text

References

Literatur
1 Koenig M. et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organisation of the DMD gene in normal and affected individuals. Cell 1987; 50: 509-17.
2 Flanigan KM. et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009; 30: 1657-66.
3 Comi GP. et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. Brain 1994; 117: 1-14.
4 Muntoni F. et al. A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. J Clin Invest 1995; 96: 693-9.
5 Figarella-Branger D. et al. Exertional rhabdomyolysis and exercise intolerance revealling dystrophinopathies. Acta Neuropathol 1997; 94: 48-53.
6 Prelle A. et al. Dystrophin deficiency in a case of congenital myopathy. J Neurol 1992; 239: 76-8.
7 Cordone G. et al. Severe dystrophinopathy in a patient with congenital hypotonia. Child’s Nerv Syst 1996; 12: 466-9.
8 Stuhrmann M. et al. Characterisation of a Xp21 microdeletion syndrome in a 2-year-old boy with muscular dystrophy, glycerol kinase deficiency and adrenal hypoplasia congenita. Hum Genet 1991; 86: 414-5.
9 Koenig M. et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989; 45: 498-506.
10 Malhotra SB. et al. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 1988; 242: 755-9.
11 Muntoni F. et al. Deletions in the 5’ region of dystrophin and resulting phenotypes. J Med Genet 1994; 31: 843-7.
12 Kerst B. et al. Heterozygous myogenic factor 6 mutation associated with myopathy and severe course of Becker muscular dystrophy. Neuromuscul Disord 2000; 10: 572-7.
13 v. Moers A. et al. Dystrophinopathy in a boy with Chediak-Higashi syndrome. Neuromuscul Disord 1998; 08: 489-94.
14 Emery AEH. Population frequencies of inherited neuromuscular diseases – a world survey. Neuromuscul Disord 1991; 01: 19-29.
15 Bushby KM. et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy, II. Correlation of phenotype with genetic and protein abnormalities. J Neurol 1993; 240: 105-12.
16 Kaminski HJ. et al. Extraocular muscles are spared in advanced Duchenne Dystrophy. Ann Neurol 1992; 32: 586-8.
17 Taylor PJ. et al. Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne Muscular Dystrophy. PLoS One 2010; 05 (01) e8803.
18 Pikó H. et al. Dystrophin gene analysis in Hungarian Duchenne/Becker muscular dystrophy families – detection of carrier status in symptomatic and asymptomatic female relatives. Neuromuscul Disord 2009; 19: 108-12.
19 Abbs S. et al. Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. Neuromuscul Disord 2010; 20: 422-7.
20 Hoogerwaard EM. et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1999; 95: 347-51.
21 Lesca G. et al. Symptomatic carriers of dystrophinopathy with chromosome X inactivation bias. Rev Neurol (Paris) 2003; 159: 775-80.
22 Culligan KG. et al. Role of dystrophin isoforms and associated proteins in muscular dystrophy. Int J Mol Med 1998; 02: 639-48.
23 Lidov HG, Selig S, Kunkel LM. Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. Hum Mol Genet 1995; 04: 329-35.
24 Feener CA, Koenig M, Kunkel LM. Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature 1989; 338: 509-11.
25 Arahata K. et al. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 1998; 333: 861-3.
26 Bonilla E. et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 1988; 54: 447-52.
27 Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-28.
28 Grunwald S, Speer A, Ackermann J, Koch I. Petri net modelling of gene regulation of the Duchenne muscular dystrophy. Biosystems 2008; 92: 189-205.
29 Straub V, Cambell KP. Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 1997; 10: 168-75.
30 Pegoraro E. et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011; 76: 219-26.
31 Constantin B, Sebille S, Cognard C. New insights in the regulation of calcium transfers by muscle dystrophin-based cytoskeleton: implications in DMD. J Muscle Res Cell Motil 2006; 27: 375-86.
32 McCarter GC, Steinhardt RA. Increased activity of calcium leak channels caused by proteolysis near sarcolemmal ruptures. J Membr Biol 2000; 176: 169-74.
33 Alderton JM, Steinhardt RA. How calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. Trends Cardiovasc Med 2000; 10: 268-72.
34 Andrade FH, Porter JD, Kaminski HJ. Eye muscle sparing by the muscular dystrophies: lessons to be learned?. Microsc Res Tech 2000; 48: 192-203.
35 Brennan JE, Clao DS, Honhui X, Aldape K, Bredt DS. Nitrit Oxide synthase complexed with and absent from skeletal muscle sarcolemma in Duchenne muscular dstrophy. Cell 1995; 82: 743-52.
36 Spencer MJ, Tidball JG. Do immune cells promote the pathology of dystrophin-deficient myopathies?. Neuromuscul Disord 2001; 11: 556-64.
37 Gorospe JR. et al. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci 1994; 122: 44-56.
38 Marques MJ, Ventura RMachado, Minatel E, Santo HNeto. Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness. Muscle Nerve 2008; 37: 61-7.
39 Bernasconi P. et al. Expression of the transforming factor-beta 1 in dystrophic patient muscles correlates with fibrosis. J Clin Invest 1995; 96: 1137-44.
40 D’Amore PA. et al. Elevated basic fibroblast growth factor in the serum of patients with Duchenne muscular dystrophy. Ann Neurol 1994; 35: 362-5.
41 v. Moers A. et al. Increased expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular dystrophy. Acta Neuropathologica 2004; 109: 285-93.
42 Deconinck N, Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007; 36: 1-7.
43 Haslett JN. et al. Gene expression profiling of Duchenne muscular dystrophy skeletal muscle. Neurogenetics 2003; 04: 163-71.
44 Eisenberg I. et al. Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci USA 2007; 104: 17016-21.
45 Bushby K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 09: 77-93.
46 James J. et al. Electrocardiographic abnormalities in very young Duchenne muscular dystrophy patients precede the onset of cardiac dysfunction. Neuromuscul Disord 2011; 21: 462-7.
47 Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008 01. CD003725.
48 Kirschner J. et al. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol 2010; 09: 1053-9.
49 Bach JR, Martinez D. Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care 2011; 56: 744-50.
50 Fayssoil A, Nardi O, Orlikowski D, Annane D. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics. Heart Fail Rev 2010; 15: 103-7.
51 Bushby K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 09: 177-89.
52 Mendell JR. et al. Myoblast transfer in the treatment of Duchenne’s muscular dystrophy [comments]. N Engl J Med 1995; 333: 832-8.
53 Palmieri B, Tremblay JP, Daniele L. Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy. Pediatr Transplant 2010; 14: 813-9.
54 Fisher KJ. et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 03: 306-12.
55 Kawano R. et al. Transduction of full-length dystrophin to multiple skeletal muscles improves motor performance and life span in utrophin/dystrophin double knockout mice. Mol Ther 2008; 16: 825-31.
56 Miura P. et al. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum Mol Genet 2009; 18: 4640-9.
57 Tinsley JM. et al. Expression of full length utrophin prevents muscular dystrophy in mdx mice. Nat Med 1998; 04: 1441-44.
58 Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).. J Child Neurol 2010; 25: 1158-64.
59 Malik V. et al. Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther Adv Neurol Disord 2010; 03: 379-89.
60 van Deutekom JC. et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10/15: 1547-54.
61 Goemans NM. et al. Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med 2011; 364: 1513-22.
62 Cirak S. et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011 Jul 22. Epub ahead of print.